Clinical Trial Search

Primary: Number of Participants With 18F-DCFPyL PET/CT Detected Sites of Metastatic Renal Cell Carcinoma (RCC) — 34 Participants

Primary: The Number of Evaluable Patients With Complete Response or Partial Response or Stable Disease for ≥10 Weeks From the First Infusion (6 Weeks After the Second Infusion)…

Primary: Objective 1: Age — 61.5 years

Primary: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 46.1; 53.4; 0; 0 percentage of participants

Primary: Postoperative Draining Time — 31; 32 days

Primary: Percentage of Eyes With Posterior Capsule Opacification Following Implantation of IOL 313 up to 8 Years — 7.9; 4.7; 17.1; 8.2 percentage of eyes

Primary: CLUE Vision — 57.1 units on a scale

Primary: Change in Fitbit Step Count Per Day — -323.5; 321.2 steps

Primary: Number of Participants With Incidence of Hemidiaphragmatic Paralysis (HDP) — 45; 3; 18; 59 participants

Primary: Full Scale IQ Score — 100.5; 100.1 score on scale

Primary: Number of Participants With Moderate to Severe Postoperative Pain — 26; 22 Participants — p=0.248

Primary: Maximum Tolerated Dose (MTD), Defined as Maximum Dose at Which the Incidence of Dose Limiting Toxicities (DLTs) During Cycle 1 is Below 20% — 800 mg BID

Primary: Change From Baseline in Gait Speed (cm/Sec) Measurements From Baseline to the End of Each Double-blind Treatment Period Based on Computerized Gait Assessment Tools…

Primary: Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve From Time Zero to 5 Hours (AUC[0-5h]) (Part A) — 1520; 1830 picomole*hour per liter (pmol*h/L)

Primary: Overall Survival (OS) — 12.52; 11.76 months — p=0.5625